|Home | About | Journals | Submit | Contact Us | Français|
Recently, the first Neisseria gonorrhoeae strain (H041) that is highly resistant to the extended-spectrum cephalosporin (ESC) ceftriaxone, the last remaining option for empirical first-line treatment, was isolated. We performed a detailed characterization of H041, phenotypically and genetically, to confirm the finding, examine its antimicrobial resistance (AMR), and elucidate the resistance mechanisms. H041 was examined using seven species-confirmatory tests, antibiograms (30 antimicrobials), porB sequencing, N. gonorrhoeae multiantigen sequence typing (NG-MAST), multilocus sequence typing (MLST), and sequencing of ESC resistance determinants (penA, mtrR, penB, ponA, and pilQ). Transformation, using appropriate recipient strains, was performed to confirm the ESC resistance determinants. H041 was assigned to serovar Bpyust, MLST sequence type (ST) ST7363, and the new NG-MAST ST4220. H041 proved highly resistant to ceftriaxone (2 to 4 μg/ml, which is 4- to 8-fold higher than any previously described isolate) and all other cephalosporins, as well as most other antimicrobials tested. A new penA mosaic allele caused the ceftriaxone resistance. In conclusion, N. gonorrhoeae has now shown its ability to also develop ceftriaxone resistance. Although the biological fitness of ceftriaxone resistance in N. gonorrhoeae remains unknown, N. gonorrhoeae may soon become a true superbug, causing untreatable gonorrhea. A reduction in the global gonorrhea burden by enhanced disease control activities, combined with wider strategies for general AMR control and enhanced understanding of the mechanisms of emergence and spread of AMR, which need to be monitored globally, and public health response plans for global (and national) perspectives are important. Ultimately, the development of new drugs for efficacious gonorrhea treatment is necessary.
Gonorrhea, caused by Neisseria gonorrhoeae (gonococcus), is the second-most-prevalent bacterial sexually transmitted infection globally. The disease is associated with high morbidity and socioeconomic consequences and remains a public health problem worldwide (36, 46; G. Schmid, presented at WHO/CDC symposium: Congenital syphilis and the 2005 WHO estimates of STI incidence and prevalence: using the second to help eliminate the first, 18th International Society for Sexually Transmitted Disease Research conference [ISSTDR], 28 June to 1 July 2009, London, United Kingdom). In the absence of a vaccine, appropriate diagnostics and antimicrobial therapy are the key elements for reduction and control of gonorrhea and the development of associated severe complications and sequelae, as well as further transmission of the infection (34, 36).
The treatment options, however, have diminished rapidly because of the emergence and worldwide spread of antimicrobial resistance (AMR) to all drugs previously used or considered first line, i.e., penicillins, narrow-spectrum cepha- losporins, tetracyclines, macrolides, and fluoroquinolones. Furthermore, rapid emergence of resistance to spectinomycin was observed when it was widely used for treatment in the past (4), and this antimicrobial is not suitable for treatment of pharyngeal gonorrhea, nor is it currently available in many countries (3, 15, 36). Accordingly, spectinomycin is not a promising candidate for first-line empirical treatment of gonorrhea. Worryingly, in recent years, susceptibility to the currently recommended first-line antimicrobials, the extended-spectrum cephalosporins (ESCs), i.e., ceftriaxone (injectable) and cefixime (oral), has also decreased globally (3, 15, 17, 36). Furthermore, for several years, cefixime treatment failures have been recognized in Japan (9, 36, 47), where cefixime was already excluded from treatment guidelines in 2006 (36). More recently, failures have also been verified in Europe (40). However, despite the fact that susceptibility to ceftriaxone (the last remaining option for empirical first-line treatment) is decreasing globally, in vitro and clinical (resulting in treatment failure of urogenital gonorrhea) resistance has been lacking (3, 15, 17, 36).
Recently, the first high-level ceftriaxone-resistant gonococcal strain (H041) was isolated from the pharynx of a female commercial sex worker in Kyoto, Japan (23). H041 displayed a MIC of ceftriaxone of 2 μg/ml. This is a very high level of resistance and, previously, only one isolate having an MIC of >0.25 μg/ml (MIC = 0.5 μg/ml) (33) has been reported worldwide. Unfortunately, it was not possible to definitively verify that H041 caused a treatment failure because a posttreatment isolate was not available; however, treatment failure seems likely (see Discussion). Furthermore, H041 belongs to multilocus sequence typing (MLST) sequence type (ST) ST7363 and is closely related to the successful gonococcal cefixime-resistant subclones of ST7363 (23), which are prevalent in Japan (24) and now are also being transmitted in Europe. Accordingly, H041 may be a subclone of the MLST ST7363 cefixime-resistant strains that has acquired additional resistance determinant(s), resulting in high-level ceftriaxone resistance. Historically, gonococcal AMR has mostly emerged in the World Health Organization (WHO) Western Pacific Region (WPR) and, in particular, in Japan. This resistance has spread rapidly, via sex tourists, long-distance truck drivers, and forced migration in the WHO WPR, to the Pacific Rim countries, including the United States, Southeast and Central Asia, Europe, and globally (36). The spread of ceftriaxone-resistant gonococcal strains worldwide will probably follow the same pattern. Consequently, it is crucial to examine in detail, including elucidation of the mechanisms causing the ceftriaxone resistance, the first high-level ceftriaxone-resistant gonococcal strain worldwide, recently isolated in Japan (H041) (23).
The most common mechanism in gonococci for decreased ESC susceptibility is alteration of the penA gene, i.e., the acquisition of a penA mosaic allele or alterations of amino acid A501 in the encoded penicillin-binding protein 2 (PBP2) (1, 3, 11, 14–18, 21, 23, 24, 27, 28, 32, 33, 36, 38, 40, 41, 44, 50). Mutations in the promoter and/or coding sequence of the repressor gene mtrR cause an overexpression of the MtrCDE efflux pump system, which further decreases ESC susceptibility (3, 11, 12, 16–18, 30, 36, 38, 43, 48, 50). Furthermore, specific porB1b mutations that alter amino acid G101 and A102 in the PorB1b porin (the penB resistance determinant) result in additional decreases in ESC susceptibility (3, 11, 16–18, 25, 26, 30, 36, 38, 50). Nevertheless, based on the relatively few studies of gonococcal isolates with decreased ESC susceptibility, polymorphisms in ponA (encoding PBP1) and pilQ (encoding the pore-forming secretin PilQ protein in the type IV pili), which both can be involved in high-level penicillin resistance, do not seem to substantially enhance the MICs of ESCs (11, 29, 45, 49, 50). At least one unknown resistance determinant exists (11, 18, 38, 50).
The aims of this study were to perform a detailed characterization, phenotypic and genetic, of the first identified high-level ceftriaxone-resistant N. gonorrhoeae strain (H041) worldwide in order to confirm this finding, to thoroughly examine its antimicrobial resistance, and to elucidate the ESC resistance mechanisms.
The high-level ceftriaxone-resistant strain H041 (23) and gonococcal strains (n = 9) selected for transformation assays to verify the resistance mechanisms, i.e., five clinical strains and four of the eight 2008 WHO N. gonorrhoeae reference strains (41), were included in this study. For gonococcal species verification of H041, morphology on selective culture medium, catalase and oxidase tests, microscopy after Gram staining, and seven species confirmatory tests (sugar utilization, HN-20 Rapid system identification [ID] test [Nissui, Tokyo, Japan], PhadeBact GC monoclonal test [Bactus AB, Solna, Sweden], PhadeBact GC monoclonal serovar test [Bactus AB, Solna, Sweden], MicroTrak N. gonorrhoeae culture confirmation test [Trinity Biotech, Wicklow, Ireland], porA pseudogene PCR , and dual-target PCR [porA and opa] ) were used. All strains were grown on GC culture medium as previously described (42).
Ceftriaxone MIC determination was performed using the Etest method (AB bioMérieux, Solna, Sweden) according to the manufacturer's instructions. The ceftriaxone MIC of H041 was also confirmed using the agar dilution method according to the Clinical and Laboratory Standards Institute (CLSI) standards (8). Finally, H041 was examined for its MICs of 29 additional antimicrobials (using the Etest method) and tested with the calibrated dichotomous sensitivity (CDS) disc diffusion method (5, 35), which is used in resistance surveillance of N. gonorrhoeae in many countries in the WHO WPR (six antimicrobials) (Table 1). β-Lactamase production was tested using nitrocefin discs. The 2008 WHO N. gonorrhoeae reference strains (41) were used for quality controls in all antimicrobial susceptibility testing.
DNA was isolated in a NorDiag Bullet instrument (NorDiag ASA Company, Oslo, Norway) using a Bugs'n Beads STI-fast kit (NorDiag ASA Company, Oslo, Norway) according to the manufacturer's instructions. For molecular epidemiological examination, strains were genotyped by means of MLST (24), porB gene sequencing, and N. gonorrhoeae multiantigen sequence typing (NG-MAST) as described previously (39). PCR and sequencing of resistance determinants, i.e., the penA, mtrR, porB1b, ponA, and pilQ genes, were performed as described elsewhere (18, 41, 45).
Multiple-sequence alignments (nucleotide and amino acid sequences) were performed using BioEdit Sequence Alignment Editor software (version 220.127.116.11). For examination of the evolutionary relationships of H041 with other penA mosaic strains displaying decreased ESC susceptibility and circulating worldwide, a phylogenetic analysis using the full-length porB sequences in H041 and previously reported penA mosaic strains (11) was performed with TREECON (version 1.3b) as previously described (39).
To confirm that the unique penA allele in H041 (penAH041) caused the high-level resistance to ceftriaxone, the full-length penAH041 was PCR amplified and transformed into nine recipient strains as previously described (24). These nine recipient strains displayed different molecular epidemiological sequence types, ceftriaxone MICs, and composition of ESC resistance mechanisms, such as penA alleles, the mtrR promoter, and penB sequences (Table 2). Briefly, the recipients were suspended in GC broth (1 × 108 cells/100 μl) and incubated with 0.2 μg of the penAH041 PCR product (after purification using a High Pure PCR product purification kit [Roche Diagnostics GmbH, Mannheim, Germany]) for 4 h. Aliquots of 10 μl and 100 μl were inoculated on GC agar with a 4-fold higher ceftriaxone concentration than the MIC of the respective recipient. After incubation, the colonies obtained were subcultured on an antimicrobial-free GC agar plate for single-clone isolation. For confirmation, the transformation assay was performed three times for each recipient.
The GenBank/EMBL/DDBJ accession numbers for the two new penA alleles reported in this paper are AB546858 and AB608050.
All conventional bacteriological diagnostic tests and the seven species confirmatory assays verified that H041 was a gonococcal strain, which was assigned to serovar Bpyust.
The results of the antimicrobial susceptibility testing using the Etest method (30 antimicrobials) and CDS disc diffusion method (six antimicrobials) are summarized in Table 1. Briefly, H041 was resistant to various antimicrobials, including all β-lactam antimicrobials (with possible exceptions of carbapenems, at least ertapenem and meropenem, and piperacillin-tazobactam, for which no breakpoints are available), fluoroquinolones, macrolides, tetracycline, trimethoprim-sulfamethoxazole, chloramphenicol, and nitrofurantoin. The MICs of all the cephalosporins, including the recommended first-line ESCs, were very high (e.g., 2 to 4 μg/ml of ceftriaxone and 8 μg/ml of cefixime). H041 did not produce any β-lactamase. The strain was, however, susceptible to spectinomycin and rifampin. Furthermore, the MICs of aminoglycosides and tigecycline were also relatively low (no breakpoints are available for these antimicrobials). The CDS disc diffusion method also identified H041 as resistant to ceftriaxone, cefpodoxime, penicillin G, tetracycline, and ciprofloxacin but susceptible to spectinomycin (Table 1).
The molecular epidemiological characterization assigned H041 as MLST ST7363 and as the not-previously described NG-MAST sequence type ST4220 (www.ng-mast.net). A phylogenetic analysis using porB sequences showed that H041 is closely related to other penA mosaic strains with decreased ESC susceptibility that have been shown to circulate worldwide (Fig. 1).
The sequencing of ESC resistance determinants showed that H041 possessed a unique penA mosaic allele (penAH041) and the previously described mtrR, penB, and ponA1 (L421P) resistance determinants. No new pilQ mutations were found. Thus, the only new resistance determinant, which consequently was suspected to cause the high ESC MICs, was penAH041 (GenBank accession number AB546858). penAH041 was highly similar (i.e., 97.6% nucleotide identity and only 12 PBP2 amino acid differences that clustered in two regions) to the previously described penA mosaic allele X that has been correlated with cefixime treatment failures in Japan. Of these 12 amino acids, five were unique compared with any gonococcal PBP2 sequence previously described, but one of these (I486) has been found in Neisseria meningitidis and Neisseria flavescens (Fig. 2). Accordingly, penAH041 contained only four PBP2 amino acid residues that have not been previously reported in any Neisseria species; compared to penA mosaic X, these consisted of A311V, T316P, A328T, and T484S (Fig. 2).
Based on their different genotypes, ceftriaxone MICs, and composition of ESC resistance determinants, nine strains were selected as recipients of penAH041 in transformation assays (Table 2).
Upon transformation with penAH041, the ceftriaxone MICs of the recipients increased to 0.125 to 8 μg/ml, i.e., by 16- to 500-fold. Accordingly, the ceftriaxone MICs of all recipients, with the exception of NG9901 (0.125 μg/ml), increased above the resistance breakpoint (>0.25 μg/ml) (8) independent of other resistance determinants. Remarkably, WHO F, which has wild-type alleles of all ESC and penicillin resistance determinants, displayed a ceftriaxone MIC of 0.5 μg/ml after transformation (500-fold MIC increase) (Fig. 3).
All single-clone transformants (derived from all recipient strains) showed mtrR, penB, and ponA sequences identical to those in the recipients. All the single-clone transformants also contained the penAH041 allele. In most transformants, the transformed penAH041 sequence was identical to the sequence in H041. However, in a few transformants, such as those derived from the WHO F and WHO M strains, some point mutations differed from the penAH041 sequence. These were considered to represent spontaneous mutations, mutations in junctions for recombination and/or belonging to the penA allele of the recipient. The majority of these mutations were nonsynonymous, and none was located in any segment of the mosaic penA allele affecting the ceftriaxone MICs. Consequently, the transformation experiments confirmed that penAH041 was the cause of the high-level ceftriaxone resistance.
The present study describes the detailed phenotypic and genetic confirmation and characterization, including elucidation of the resistance mechanisms, of the first identified N. gonorrhoeae strain (H041) displaying high-level resistance to ceftriaxone worldwide. H041 was isolated from a female commercial sex worker in Japan (23), and the ceftriaxone MIC of H041 was 4- to 8-fold higher than any previously observed. Ceftriaxone is also the last remaining option for empirical first-line treatment of gonorrhea. Accordingly, N. gonorrhoeae has now shown its ability to develop resistance to ceftriaxone also and, although the biological fitness of ceftriaxone resistance in N. gonorrhoeae remains unknown, the gonococcus may become a true superbug that initiates a future era of untreatable gonorrhea.
Although a posttreatment isolate was unavailable (only one specimen positive with SDA [ProbeTec ET; Becton-Dickinson], sampled 2 weeks after treatment) to definitively verify treatment failure using 1 g ceftriaxone intravenously (23), it seems likely that this was the first gonorrhea clinical failure caused solely by high resistance of the bacteria to ceftriaxone, based on the posttreatment positive-SDA sample (all residual gonococcal DNA is expected to be eliminated before 2 weeks posttreatment) (2), the very high ceftriaxone MIC, and all available data regarding pharmacodynamic parameters for ESCs. Thus, according to Monte Carlo simulations, the 1 g ceftriaxone intravenously that was used for treatment (in full concordance with treatment recommendations for urogenital and pharyngeal gonorrhea in the Japanese treatment guidelines) results in median times of free ceftriaxone above the MIC (fT>MIC) of only 6.0 h (0 to 20.3 h) and 0 h (0 to 5.6 h) for the detected MICs of 2 μg/ml (agar dilution method) and 4 μg/ml (Etest method), respectively (6). Accordingly, using 1 g ceftriaxone for treatment, the ceftriaxone MIC of H041 will make the strain escape eradication in most (if not all) patients. Furthermore, this was a case of pharyngeal gonorrhea, which is substantially harder to treat than urogenital gonorrhea (3, 36), and the infection probably resolved spontaneously within 3 months. Nevertheless, despite the fact that a clinical history was recorded, re-reinfection cannot be completely excluded, especially as the patient was a commercial sex worker.
The resistance determinants causing the high ESC MICs in H041 were also elucidated. The unique penAH041 mosaic allele was found to be responsible; upon transformation of penAH041 into recipients with different ESC MICs and resistance mechanisms, their ceftriaxone MICs increased to 0.125 to 8 μg/ml, i.e., by 16-fold to 500-fold. Nevertheless, additional resistance determinants, especially mtrR and penB (and “factor X,” i.e., the still unidentified determinant), were needed to reach the same level of ceftriaxone MIC as H041, a synergy that was previously reported (18, 36, 50). Factor X was not transformable using the H041 genome (data not shown), which has also previously been described using other gonococcal genomes (18, 50). penAH041 is highly similar to the previously described penA mosaic allele X (causing ceftriaxone MICs of only 0.064 to 0.125) (Table 2), which has been correlated with cefixime treatment failures in Japan, having only 12 PBP2 amino acid differences clustering in two regions. Of these 12 amino acids, only four have not been previously reported in any Neisseria species; compared with penA mosaic X, these consist of A311V, T316P, A328T (in region A), and T484S (in region B) (Fig. 2). It was also confirmed that transformation of only the penAH041 region A into the recipients caused, for most, as high a ceftriaxone MIC as transforming the full-length penAH041 (data not shown). Although further confirmatory studies are needed, it is highly probable that A311V and T316S are the alterations causing the high ceftriaxone resistance, i.e., due to the proximity to the β-lactam active site in PBP2. Despite this fact, the MICs of some β-lactam antimicrobials, such as penicillins (especially piperacillin-tazobactam) and carbapenems (particularly ertapenem and meropenem), were surprisingly low. penAH041 could also easily be transformed to other gonococcal strains in cocultivation experiments (data not shown) performed as previously described (24), which shows that this ceftriaxone resistance can rapidly spread within the N. gonorrhoeae population.
H041 seems to represent a subclone of the previously described MLST ST7363 cefixime-resistant N. gonorrhoeae circulating in Japan (23, 24). This clone has caused treatment failures using oral ESCs, has successfully spread worldwide, and now seems to have evolved further and developed resistance to ceftriaxone as well. The fear is that this ceftriaxone-resistant subclone will now spread in Japan, to WHO WPR countries, to Pacific Rim countries, and globally, which has been the scenario for emergence and worldwide spread of most gonococcal AMR. Based on previous experience (e.g., for fluoroquinolones), AMR can be widely disseminated internationally only 1 or 2 decades after the first emergence of AMR in WHO WPR (34, 36). The finding of this single high-level ceftriaxone-resistant gonococcal strain is important, especially because it was identified in a female commercial sex worker belonging to a high-risk, frequently transmitting population and because no national gonococcal antimicrobial resistance surveillance programs (including no sentinel sites for identification of gonorrhea treatment failures) are active in Japan. Accordingly, the strain should have excellent opportunities for a rapid spread. An enhanced but still limited gonococcal antimicrobial resistance surveillance in Kyoto, Japan, was initiated after the finding of H041; however, any secondary spread of H041 (or additional treatment failures) has yet not been identified. Despite the suboptimal Japanese surveillance systems, this fact may indicate that H041 has a lower biological fitness that results in limited further spread. Accordingly, the biological fitness of H041, compared to that of its wild type lacking penAH041 that causes the ceftriaxone resistance, would be valuable to examine in a well-designed study, i.e., investigating quantitatively the fitness in vitro (different culture media, solid and liquid based) and also in an appropriate animal model, i.e., in vivo.
Nevertheless, N. gonorrhoeae has now shown its ability to develop resistance to ceftriaxone also, in which case gonorrhea may become untreatable in certain circumstances; although the biological fitness of H041 remains unknown, a serious public health problem seems to be approaching. To at least limit the spread of ESC (cefixime and ceftriaxone) resistance, timely and decisive multidisciplinary and multicomponent public health actions are essential not only in Japan but also globally. A recent expert review described WHO initiatives and approaches to AMR containment and how to meet public health challenges of untreatable gonorrhea (36). Nevertheless, to succeed with any AMR containment, enhanced gonorrhea control activities are needed to reduce the burden of infection (36). Furthermore, it is crucial to explore options, in industrialized settings as well as in less-resourced settings, for future treatment of ESC-resistant gonorrhea. This includes exploration of optimized dose regimens of presently used antimicrobials, new antimicrobials (or rediscovery of old drugs, such as gentamicin, ertapenem, and perhaps, piperacillin-tazobactam in emergent situations of ESC-resistant N. gonorrhoeae) or other substances, and combination therapy (6, 7, 19, 20, 22, 31, 36, 37; M. Unemo and J. Tapsall, unpublished data).
In conclusion, the first high-level ceftriaxone-resistant N. gonorrhoeae strain has now been characterized in detail, including an elucidation of its resistance mechanisms. Accordingly, N. gonorrhoeae has now shown its ability to develop ceftriaxone resistance also and, although the biological fitness of ceftriaxone resistance in N. gonorrhoeae remains unknown, the gonococcus may soon become a true superbug that initiates a future era of untreatable gonorrhea. To at least slow the spread of ESC (cefixime and ceftriaxone) resistance, a reduction in global gonorrhea burden by enhanced disease prevention and control activities is crucial. As well, the implementation of much wider strategies for general AMR control, better understanding of the mechanisms and global monitoring of the emergence and spread of AMR, and global and national public health response plans (including sustainable clinical, microbiological, and epidemiological components) are needed. Any such plan alone will most probably not be able to prevent the emergence, establishment, and spread of ceftriaxone resistance; nevertheless, these plans will be valuable to delay and limit a global spread of ESC resistance (cefixime and ceftriaxone). Ultimately, a major focus important for public health globally is the timely development of effective new drugs (for single or combined use) for the treatment of gonorrhea.
The present work was supported by grants-in-aid from the Ministry of Health, Labor and Welfare of Japan (to M.O.) and by grants from the Örebro County Council Research Committee and the Foundation for Medical Research at Örebro University Hospital, Sweden (to M.U.).
We are grateful to Yuko Watanabe (Kanagawa Prefectural Institute for Public Health) for providing clinical isolates and to Leslie Shaps for linguistic revision of the manuscript.
The work was performed at the Department of Bacteriology I, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan, and the Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, SE-701 85 Örebro, Sweden.
Published ahead of print on 16 May 2011.
†The authors have paid a fee to allow immediate free access to this article.